Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection

Journal of Hypertension

29 December Dec 2017 19 days ago
  • Tremoli E, Sironi L, Gelosa P

The simultaneous presence of cardiac and renal diseases is a pathological condition that leads to increased morbidity and mortality. Several lines of evidence have suggested that lipid dysmetabolism and mitochondrial dysfunction are pathways involved in the pathological processes affecting the heart and kidney. In the salt-loaded spontaneously hypertensive stroke-prone rat (SHRSP), a model of cardiac hypertrophy and nephropathy that shows mitochondrial alterations in the myocardium, we evaluated the cardiorenal effects of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist that acts by modulating mitochondrial and peroxisomal fatty acid oxidation.

Reference
Castiglioni L, Pignieri A, Fiaschè M, Giudici M, Crestani M, Mitro N, Abbate M, Zoja C, Rottoli D, Foray C, Fiordaliso F, Guerrini U, Tremoli E, Sironi L, Gelosa P. Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection. J Hypertens 2017 Dec 22. doi: 10.1097/HJH.0000000000001651. [Epub ahead of print]

Go to PubMed